Highlights•Idiopathic pulmonary fibrosis (IPF) is a progressive disease with no cure.•A
number of clinical trials of potential treatments have recently been completed.•Pirfenidone …

Idiopathic pulmonary fibrosis (IPF) is a devastating condition with a 5‐year survival of
approximately 20%. The disease primarily occurs in elderly patients. IPF is a highly …

Idiopathic pulmonary fibrosis (IPF) is a deadly disease with a median survival of
approximately three years in historical cohorts. Despite increased knowledge of disease …

Over the past two and a half decades, many clinical trials have been designed to determine
the safety and efficacy of pharmacotherapy for patients with idiopathic pulmonary fibrosis …

Idiopathic pulmonary fibrosis (IPF) is a progressive and ultimately fatal disease. A major
breakthrough in treatment came when, after decades of clinical trials which failed to identify …

The last years have led to advances in the therapeutic management of idiopathic pulmonary
fibrosis (IPF), mainly through the discovery of new pathological pathways and drugs and …

Over the past decade, there has been a cohesive effort from patients, physicians, clinical
and basic scientists, and the pharmaceutical industry to find definitive treatments for …

Introduction: Idiopathic pulmonary fibrosis (IPF) is a lung limited, progressive fibrotic disease
with a poor prognosis. The cause is unknown, and currently there is no treatment that …

Introduction: While many pharmacologic therapies for the treatment of idiopathic pulmonary
fibrosis (IPF) have been evaluated via randomized, placebo-controlled clinical trials (RCTs) …

Currently many questions remain regarding the use of pirfenidone and nintedanib in IPF,
including which drug to prescribe, the optimal patient population to treat, the duration of …